Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Residual Inflammatory Risk-Guided Low-dose Colchicine Therapy in Elderly Patients With Multivessel Coronary Artery Disease: A Multicenter Randomized Controlled Trial

NCT06025071 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences, Fuwai Hospital as lead sponsor.

NCT NCT06025071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06025071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Residual Inflammatory Risk-Guided Low-dose Colchicine Therapy in Elderly Patients With Multivessel Coronary Artery Disease: A Multicenter Randomized Controlled Trial
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
September 30, 2023
Completion date
October 31, 2025
Enrollment
800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

c-reactive protein, elderly patients, multivessel coronary artery disease, percutaneous coronary intervention